Skip to content

Vir Biotechnology

US · VIR #2824 by market cap Listed 2019
8.39 -0.48 -5.41%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 25 in the most recent period (2026/Q3).
  • Total institutional ownership fell 3.1 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
87.04% -3.06pp
Institutions
317 +25
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund47.33%
VC/PE Fund19.92%
Hedge Fund13.43%
Individual/Insider4.23%
Public Company3.35%
Private Company0.97%
Insurance Company0.92%
Government Pension Fund0.77%
Endowment Fund0.23%
Other8.84%

Top holders as of 2026-09-30

BlackRock 12.21% · 20.91M sh
Vanguard Portfolio Management, LLC 7.02% · 12.02M sh
Arch Venture Partners, L.P. 6.95% · 11.90M sh
SB Investment Advisers (UK) Limited 6.39% · 10.95M sh
GSK Equity Investments, Limited 4.99% · 8.55M sh
State Street Global Advisors 4.57% · 7.82M sh
Vanguard Capital Management, LLC 3.77% · 6.45M sh
Point72 Asset Management, L.P. 3.31% · 5.67M sh
George Scangos 2.21% · 3.78M sh
Dimensional Fund Advisors 1.94% · 3.32M sh
Geode Capital Management, LLC 1.98% · 3.35M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 20 buys · 27 sells

NameRoleStake
George Scangos Former Director 2.21%
Vicki Sato Independent Chairperson 0.62%
Marianne De Backer Chief Executive Officer 0.58%
Robert Taylor Nelsen Former Independent Director 0.36%
Vanina de Verneuil General Counsel 0.06%
Ann Hanly Former Executive VP & Chief Technology Officer 0.04%
Brent Sabatini Senior VP, Principal Accounting Officer & Chief Accounting Officer 0.04%
Robert J. More Independent Director 0.02%
Charles Sigal Independent Director 0.01%
Jason O'Byrne -- 0.01%
Jeffrey Hatfield Independent Director 0.01%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-02 Vanina de Verneuil General Counsel Open Market Disposition -3,750 $11.10–11.33
2026-11-02 Vanina de Verneuil General Counsel Intent to Sell (Form 144) -2,407 $11.10
2026-11-01 Vanina de Verneuil General Counsel Intent to Sell (Form 144) -1,343 $11.33
2026-10-26 Suzanne Topalian Director Other Acquisition +12,731 --
2026-10-26 Suzanne Topalian Director Other Derivative Acquisition +25,462 $11.57
2026-10-26 Suzanne Topalian Director Initial Statement of Beneficial 0 --
2026-10-04 Aziz Sawaf Executive VP, CFO & Principal Financial Officer Initial Statement of Beneficial 0 --
2026-09-16 Jason O'Byrne -- Intent to Sell (Form 144) -19,357 $11.00
2026-09-08 Jason O'Byrne -- Intent to Sell (Form 144) -28,333 $11.13
2026-08-24 Jason O'Byrne -- Intent to Sell (Form 144) -23,148 $10.48
2026-08-23 Jason O'Byrne -- Intent to Sell (Form 144) -14,352 $9.90
2026-08-20 Jason O'Byrne -- Intent to Sell (Form 144) -25,000 $9.81
2026-08-10 Alta Partners LP -- Other Acquisition +8,000 --
2026-08-10 Robert J. More Independent Director Other Disposition -8,000 --
2026-06-28 Sona Saira Ramasastry Former Independent Director Intent to Sell (Form 144) -16,000 $10.32
2026-06-08 Timothy Coughlin Director Other Acquisition +16,000 --
2026-06-08 Timothy Coughlin Director Other Derivative Acquisition +16,000 $8.51
2026-06-08 Timothy Coughlin Director Initial Statement of Beneficial 0 --
2026-05-31 Janet Napolitano Independent Director Automatic Disposition -3,200 $9.45
2026-05-31 Brent Sabatini Senior VP, Principal Accounting Officer & Chief Accounting Officer Automatic Disposition -379 $9.45

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Vir Biotechnology discussion 0 comments

Add a comment